Ed­i­tas Med­i­cine pads run­way with $50M up­front from Ver­tex for Cas9 li­cense

As Ed­i­tas Med­i­cine at­tempts to catch up to the his­toric ap­proval of Ver­tex Phar­ma­ceu­ti­cals and CRISPR Ther­a­peu­tics’ gene-edit­ed sick­le cell treat­ment, the biotech will get $50 mil­lion in cash from the pack’s leader.

Ver­tex will dole out the up­front pay­ment for a non-ex­clu­sive li­cense to Ed­i­tas’ Cas9 gene edit­ing tech­nol­o­gy as it re­lates to ex vi­vo gene edit­ing med­i­cines that tar­get the BCL11A gene for sick­le cell dis­ease and the blood dis­or­der be­ta tha­lassemia, the com­pa­nies said Wednes­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.